Abbreviated Name

PCA3 Ref Set App: Chinnaiyan (2020)

Lead Investigator

Chinnaiyan, Arul M. — University of Michigan

Coordinating Investigator

Feng, Ziding — Fred Hutchinson Cancer Center

Involved Investigators

• Feng, Ziding — Fred Hutchinson Cancer Center
• Chinnaiyan, Arul M. — University of Michigan

Abstact

Aims

Biopsy-naïve men provided post-digital rectal examination (DRE) urine prior to biopsy. MPS was calculated using the validated, locked multivariable model including only serum PSA, urinary PCA3, and urinary TMPRSS2:ERG. The MPS threshold approximating 95% sensitivity for GG ≥2 cancer was identified in a training cohort, and performance was measured in two external validation cohorts. We assessed the (i) overall biopsy-referral population and (ii) population meeting guideline-based testing criteria (ie, PSA 3-10; or PSA <3 with suspicious DRE).

Analytic Method

Biomarkers

• No biomarkers available at this time for this protocol

Data Collections

• No data available at this time for this protocol

 Team Project

Protocol ID

477

Protocol Type

Validation

Field of Research

Genomics

Collaborative Group

Prostate and Urologic Cancers Research Group

Cancer Types

• Malignant neoplasm of prostate